CT 101 - Carmell Corporation
Alternative Names: Bone healing accelerant - Carmell Corporation; CT-101 - Carmell Corporation; Long-bone fracture treatment - Carmell Corporation; Tibia fracture treatment - Carmell CorporationLatest Information Update: 28 May 2024
At a glance
- Originator Carnegie Mellon University
- Developer Carmell Corporation
- Class Blood proteins
- Mechanism of Action Fibroblast growth factor stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Fracture
- Phase I Joint disorders
- Preclinical Periodontal disorders
- No development reported Spinal disorders
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Spinal-disorders in USA
- 28 Feb 2023 No recent reports of development identified for clinical-Phase-Unknown development in Fracture(Adjunctive treatment) in South Africa
- 05 Jan 2023 Carmell therapeutics has 21 patent issued worldwide